Insider Trading April 17, 2026 05:52 PM

Morgan Stanley Co-President Sells $2.78M in Stock as Shares Trade Near 52-Week High

Daniel Simkowitz offloads 14,690 shares amid strong quarterly results and analyst optimism

By Leila Farooq MS
Morgan Stanley Co-President Sells $2.78M in Stock as Shares Trade Near 52-Week High
MS

Daniel A. Simkowitz, co-president of Morgan Stanley, sold 14,690 shares of the bank's common stock on April 17, 2026, realizing about $2.78 million. The sale occurred as the stock traded close to its 52-week high following a 77.6% year-over-year gain and came after the firm reported stronger-than-expected first-quarter results that prompted several analyst price-target revisions.

Key Points

  • Daniel A. Simkowitz sold 14,690 shares on April 17, 2026, for approximately $2.78 million at prices between $188.72 and $189.65.
  • The sale came as Morgan Stanley's stock traded close to a 52-week high of $194.59 after a 77.6% gain over the past year, and the filing also records an additional disposal of 8,000 shares.
  • Morgan Stanley reported record Q1 2026 results: EPS $3.43 (13.58% above expectations) and revenue of $20.58 billion, leading to multiple brokerages reaffirming or raising targets.

Daniel A. Simkowitz, who serves as co-president of Morgan Stanley, sold 14,690 shares of common stock on April 17, 2026, for roughly $2.78 million, according to a Form 4 filing with the Securities and Exchange Commission. The reported trade executed at prices between $188.72 and $189.65.

The timing of the sale coincided with Morgan Stanley shares trading near their 52-week high of $194.59, after the stock had rallied approximately 77.6% over the prior 12 months. The Form 4 filing also shows Simkowitz disposed of an additional 8,000 shares of common stock in the same reporting period.

Following these transactions, Simkowitz's direct holdings stand at 365,802.079 shares of Morgan Stanley common stock. He additionally holds 1,805.331 shares indirectly through a 401(k) plan, as disclosed in the filing.

Independent analysis noted in the filing's accompanying commentary indicates that, at current market levels, Morgan Stanley's stock appears slightly overvalued. The same analysis references the availability of an in-depth Pro Research Report for Morgan Stanley, among more than 1,400 U.S. equities, for investors seeking expanded research on the company.


These insider sales occurred in the aftermath of Morgan Stanley reporting record results for the first quarter of 2026. The firm posted earnings per share of $3.43, beating the consensus expectation of $3.02 by 13.58%. Revenue totaled $20.58 billion, above the anticipated $19.7 billion.

Following the quarterly disclosure, several brokerages updated their views and targets. UBS reiterated a Buy rating with a price target of $196.00. Keefe, Bruyette & Woods raised its price target to $218 from $210 while maintaining an Outperform rating, citing continued revenue growth across Morgan Stanley's core businesses. Citizens reiterated a Market Perform rating and highlighted the firm's favorable positioning alongside improving key performance indicators in trading, investment banking, and Global Wealth Management.

Within the company, the wealth management division reported total revenues slightly ahead of Street expectations and delivered a pre-tax margin of 30%. Morgan Stanley's return on tangible common equity was reported at 27%, a metric the firm attributed to the performance of its wealth management operations.

Taken together, the insider sale, the near-term valuation commentary, and the quarter's robust financials provide a snapshot of activity inside and outside the firm: executive selling at elevated share prices, an analyst view that current valuation may be modestly rich, and operational results that prompted positive analyst reactions and target revisions.

Risks

  • Insider selling at or near multi-month highs may raise questions about executive liquidity needs or portfolio rebalancing - this can affect investor perception of the stock (affects financials and capital markets).
  • Analyst commentary that the stock appears slightly overvalued introduces valuation risk for equity investors, particularly given recent strong price appreciation (affects equity markets and wealth management portfolios).
  • Future performance that falls short of the recent strong quarter could prompt downward revisions to expectations or price targets, impacting trading and investment-banking sentiment (affects trading and investment banking sectors).

More from Insider Trading

Aehr Test Systems Director Disposes $139,922 in Shares; Company Posts Record Order and Strong Bookings Apr 17, 2026 StandardAero HR Chief Sells $20.9K in Shares as Company Posts Strong Q4 2025 Results Apr 17, 2026 Apogee CFO Disposes $180,000 in Stock as Shares Trade Near Yearly High Apr 17, 2026 IBEX Director Disposes $162,809 in Shares Amid Active Buybacks and Strong Quarterly Results Apr 17, 2026 StandardAero Executive Disposes of $10,670 in Shares Amid Recent Option Grants and Strong Q4 Results Apr 17, 2026